• Home
  • People
    • Matthew Meyerson
    • Scientific Staff
    • Research Fellows
    • Students
    • Lab Alumni
  • Research
    • Cancer Genomic Technology
    • Genomics of Lung and Other Cancers
    • Lung Cancer Biology
    • Genome-inspired Cancer Drug Discovery
    • Cancer Microbiome
    • Ribonucleotides and the Inflammatory Response
  • Datasets & Tools
  • Publications
    • Primary Articles
    • Lab and Collaborative Articles
    • Review Articles
  • News
  • Contact
  • Lab Only
    • Whiteboard
    • Questions/Help
    • Protocols
    • Calendar
    • Interesting Science
Meyerson Lab - Cancer Genomics and Genome-Inspired Discovery

Meyerson Laboratory
CANCER GENOMICS AND GENOME-INSPIRED DISCOVERY

Picture
Picture

We strive to discover genomic and infectious causes for human cancers and apply these discoveries to understand mechanisms of cancer pathogenesis and to improve cancer diagnosis and treatment. A particular focus is lung cancer pathogenesis and targeted therapy, including new therapeutic compounds and modalities. We use a combination of experimental discovery ,including biochemical, functional genomic, and animal models, and computational genomic techniques. Current projects in the lab include:

Germline risk and somatic influence in lung adenocarcinoma.
Comprehensive characterization of lung cancer driver mutations.
Analysis of non-coding genome using long-read sequencing
The cancer microbiome and its role in pathogenesis and treatment
Targeted cancer therapeutics and their mechanisms of action
Functional and genomic analysis of lung cancer genes and alterations

Previous projects in the lab have led to exciting and novel discoveries such as:
  • Lung cancer oncogenes like BRAF, EGFR, SOX2, and NKX2-1 and tumor suppressors like RBM10 and CMTR2
  • Non-coding enhancers near MYC and KLF5 in lung cancer and in androgen receptors in prostate cancer
  • Analysis of somatic mutations in EGFR in lung cancer in populations of European, African, and East Asian descent, as well as its correlation with Native American ancestry in populations from Latin America
  • Pan-institutional analysis of large data cohorts including in breast, squamous lung cancer, lung adenocarcinoma, and cervical cancer, and pan-cancer analysis of copy number alterations through involvement in TCGA
  • Functional and genomic analysis of aneuploidy in lung cancer
  • Fusobacterium's enrichment in colorectal cancer and its role in metastasis and response to antibiotics
  • Clinical therapies targeting exon 20 mutations in EGFR, and  "velcrins" in the PD3EA-SLFN12 complex
  • Computational methods such as Oncotator, PathSEQ, ABSOLUTE, GISTIC, and ASCETS
  • Experimental improvements in cfDNA and single-cell sequencing​
We are always looking for talented and enthusiastic people to join our group at all skill levels. We are based at Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute in the Greater Boston area.

Currently, the lab includes 15 postdocs, 10 students at levels from undergraduate to graduate level, and over 15 scientific and administrative staff at all levels of their career. Trained in the outstanding scientific and collaborative environments of Kendall Square/MIT and the Harvard/Longwood Medical Area, Meyerson lab alums occupy leadership positions today in academia, industry, and clinical & research centers within the United States and abroad. 

Are you passionate about cancer research and genomics? Do you dream of coming up with novel insights into cancer biology or a new drug to treat cancer?  Do you want to learn and broaden your skills in scientific exploration? If so, join our team by sending your <whatever Julie needs>! 
Citations of the above images
 HOME | PEOPLE | RESEARCH | PUBLICATIONS | PICTURES | NEWS | LAB ONLY | CONTACT

©2015 Meyerson Laboratory Dana-Farber Cancer Institute